Poonam Giri

Ahmedabad, GJ, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Saroglitazar, a novel PPAR-α/γ agonist, modulates thyroid hormone homeostasis through hepatic UGT expression in wistar rats.

Saroglitazar, a novel PPAR-α/γ agonist, modulates thyroid hormone homeostasis through hepatic UGT expression in wistar rats.

Journal: Chemico-biological interactions

Published: August 29, 2025

Highly Sensitive and Selective Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study.

Highly Sensitive and Selective Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study.

Journal: Biomedical chromatography : BMC

Published: August 27, 2025

Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity.

Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity.

Journal: Bioorganic & medicinal chemistry letters

Published: March 26, 2024

Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.

Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.

Journal: European journal of drug metabolism and pharmacokinetics

Published: July 10, 2022

Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor.

Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor.

Journal: Bioorganic & medicinal chemistry letters

Published: February 18, 2022

ZY12201, A Potent TGR5 Agonist: Identification of a Novel Pan CYP450 Inhibitor Tool Compound for In-Vitro Assessment.

ZY12201, A Potent TGR5 Agonist: Identification of a Novel Pan CYP450 Inhibitor Tool Compound for In-Vitro Assessment.

Journal: Drug metabolism letters

Published: November 11, 2021

Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B0AT1 (SLC6A19).

Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B0AT1 (SLC6A19).

Journal: Bioorganic & medicinal chemistry letters

Published: August 12, 2021

Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.

Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.

Journal: Bioorganic & medicinal chemistry letters

Published: July 28, 2020

Simultaneous determination of sacubitrilat and fimasartan in rat plasma by a triple quad liquid chromatography-tandem mass spectrometry method utilizing electrospray ionization in positive mode.

Simultaneous determination of sacubitrilat and fimasartan in rat plasma by a triple quad liquid chromatography-tandem mass spectrometry method utilizing electrospray ionization in positive mode.

Journal: Biomedical chromatography : BMC

Published: June 29, 2020

ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.

ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.

Journal: Pharmacology research & perspectives

Published: November 27, 2019

Relevance of preclinical rodent pharmacokinetics in the selection of a companion antibiotic for combining with beta-lactamase inhibitor.

Relevance of preclinical rodent pharmacokinetics in the selection of a companion antibiotic for combining with beta-lactamase inhibitor.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: November 23, 2019

Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors.

Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors.

Journal: ACS medicinal chemistry letters

Published: September 19, 2019

Showing 1-12 of 31

Last Updated: 09/26/2026